← Companies
INDIVIOR PLC
Data as of Sep 17, 2026
Reported federal lobbying
$2.4M
24 filings · latest Jul 20, 2026
Federal contracts since 2024
$5K
3 awards · latest Apr 29, 2026
Lobbying
$2,390,000 in reported federal lobbying spend across 24 quarterly filings, most recently Jul 20, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.
Spend by issue
- Health Issues$1.5M10 filings
- Medicare/Medicaid +1$320K6 filings
- Pharmacy +1$150K3 filings
- Pharmacy$100K2 filings
Latest filings, Apr 2026 onward
| Filed | Registrant and subject | Amount |
|---|---|---|
| Jul 20, 2026 | INDIVIOR INC Health Issues Issues related to regaining status for long acting injectables on the BOP formulary, and changes to CMS bundled payments. | $250,000 |
| Jul 20, 2026 | JEFFREY J. KIMBELL & ASSOCIATES, INC. for INDIVIOR INC. Health Issues Issues related to substance use disorder | $10,000 |
| Apr 20, 2026 | INDIVIOR INC Health Issues Issues related to regaining status for long acting injectables on the BOP formulary, and changes to CMS bundled payments. | $250,000 |
| Apr 20, 2026 | CROSSROADS STRATEGIES, LLC for INDIVIOR INC. Unspecified | $30,000 |
| Apr 17, 2026 | JEFFREY J. KIMBELL & ASSOCIATES, INC. for INDIVIOR INC. Health Issues Issues related to substance use disorder | $10,000 |
| Apr 16, 2026 | DLA PIPER LLP (US) for INDIVIOR INC. Medicare/Medicaid · Health Issues H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, incl | $20,000 |